Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Ósea phase II trial

British Journal of Haematology

Volumn 120, Issue 2, 2003, Pages 296-303

  Lahuerta, Juan José ^a   Grande, Carlos ^a   Martínez Lopez, Joaquín ^a   De La Serna, Javier ^a   Toscano, Rosa ^a   Cruz Ortiz, María ^a   Larregla, Santiago ^a   Conde, Eulogio ^b   Insunza, Andrés ^b   Gonzalez San Miguel, José David ^c   Bargay, Juan ^d   Cabrera, Rafael ^e   Carlos García Ruiz, Juan ^f   Albó, Carmen ^g   García Alonso, Luis ^k   Solano, Fernando ^h   Vivancos, Pilar ⁱ   León, Angel ^k   San Miguel, Jesús ^j  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g HOSPITAL XERAL CALDE   (Spain)

^h Hospital Ntra Sra del Prado   (Spain)

ⁱ Institut Clinica Corachan   (Spain)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k NONE

more..

Author keywords

Complete remission; Conditioning regimens; Myeloma; Survival; Tandem transplants

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; REOPERATION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0037278820     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04067.x     Document Type: Article

References (27)

1. Alexanian, R., Weber, D., Giralt, S., Dimopoulos, M., Delasalle, K., Smith, T. & Champlin, R. (2001) Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplantation, 27, 1037-1043.
2. Attal, M., Huguet, F., Schlaifer, D., Payen, C., Laroche, M., Fournie, B., Mazieres, B., Pris, J. & Laurent, G. (1992) Intensive combined therapy for previously untreated aggressive myeloma. Blood, 79, 1130-1136.
3. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91-97.
4. Attal, M., Harousseau, J.L., Facon, T., Michaux, J.I., Guilhot, F., Fruchard, C.C., Fuzibet, J.G., Hulin, C.C., Caillot, D.D., Dorvaux, V.V., Cahn, J.Y., Grobois, B.B., Stoppa, A.M., Ifrah, N.N. & Sotto, J.J. (2000) Single versus double transplantation m myeloma: a prospective randomized trial of the Inter-groupe Francophone du Myelome. Blood, 96, 557.
5. Badros, A., Barlogie, B., Morris, C., Desikan, R., Martin, S.R., Munshi, N., Zangari, M., Toor, A., Cottler-Fox, M., Fassas, A., Aniassie, E., Schichman, S. & Tricot, G. (2001) High response rate in refractory and poor-risk multiple myeloma after allo-transplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood, 97, 2574-2579.
6. Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, I., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. & Crowley, J. (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, 55-65.
7. Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D. & Tricot, G. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98, 492-494.
8. Bjorkstrand, B., Svensson, H., Goldschmidt, H., Ljungman, P., Apperley, J., Mandelli, F., Marcus, R., Boogaerts, M., Alegre, A., Remes, K., Cornelissen, I.I., Blade, J., Lenhoff, S., Iriondo, A., Carlson, K., Volta, L., Littlewood, T., Goldstone, A.H., San Miguel, I., Schattenberg, A. & Gahrton, G. (2001) Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 27, 511-515.
9. Blade, I., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz. M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. British Journal of Haematology, 102, 1115-1123.
10. Blade, J., Esteve, J., Rives, S., Martinez, C., Rovira, M., Urbano-Ispizua, A., Marin, P., Carreras, E. & Montserrat, E. (2000) Highdose therapy autotransplantation/intensification vs. continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplantation, 26, 845-849.
11. Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleaven, J., Viner, C. & Malpas, J. (1994) High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. Journal of Clinical Oncology, 12, 759-763.
12. Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P. & Crowley, J. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95, 4008-4010.
13. Garban, F., Attal, M., Rossi, J.F., Payen, C., Fegueux, N. & Sotto, J.J. (2001) Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. Leukemia, 15, 642-646.
14. Goldschmidt, H., Martin, H., Serke, S., Hegenbart, U., Glasmacher, A., Ko, Y., Meier, K.R., Schultze, W., Hänel, A., Rudolph, C., Gerhartz, H., Hastka, J., Wilhelm, M., Gieseler, F., Bornhäuser, M., Ehninger, R., Hehlmann, G., Hoelzer, D., Huhn, D., Haas, R. & Ho, A.D. (1999) Tandem autologous transplantation for multiple myeloma: first results of a German multicentre study. Bone Marrow Transplantation, 23, s133.
15. Hus, M., Dmoszynska, A., Soroka-Wojtaszko, M., Jawniak, D., Legiec, W., Ciepnuch, H., Hellmann, A., Wolska-Smolen, T., Skotnicki, A. & Manko, J. (2001) Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica, 86, 404-408.
16. Jagannath, S., Vesole, D.H., Glenn, L., Crowley, J. & Barlogie, B. (1992) Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood, 80, 1666-1672.
17. Lahuerta, J.J., Martinez-Lopez, J., Serna, J.D., Blade, J., Grande, C., Alegre, A., Vazquez, L., Garcia-Laraña, J., Sureda, A., Rubia, J.D., Conde, E., Martinez, R., Perez-Equiza, K., Moraleda, J.M., Leon, A., Besalduch, J., Cabrera, R., Miguel, J.D., Morales, A., Garcia-Ruiz, J.C., Diaz-Mediavilla, J. & San-Miguel, J. (2000) Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. British Journal of Haematology, 109, 438-446.
18. Lahuerta, J.J., Grande, C., Blade, J., Martinez-Lopez, J., de la Serna, J., Alegre, A., Garcia, L.J., Caballero, D., Marin, J., Perez-Lopez, C., Sureda, A., Escudero, A., Cabrera, R., Conde, E., Garcia-Ruiz, J.C., Perez-Equiza, K., Hernandez, F., Palomera, L., Leon, A., Giraldo, P., Solano, C., Bargay, J. & San Miguel, J. (2002) Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. Leukemia and Lymphoma, 43, 67-74.
19. Lemoli, R.M., Fortuna, A., Motta, M.R., Rizzi, S., Giudice, V., Nannetti, A., Martinelli, G., Cavo, M., Amabile, M., Mangianti, S., Fogli, M., Conte, g. & Tura, S. (1996) Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood, 87, 1625-1634.
20. Lemoli, R.M., Martinelli, G., Zamagni, E., Motta, M.R., Rizzi, S., Terragna, C., Rondelli, R., Ronconi, S., Curti, A., Bonifazi, F., Tura, S. & Cavo, M. (2000) Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood, 95, 2234-2239.
21. Lenhoff, S., Hjorth, M., Holmberg, E., Turesson, I., Westin, J., Nielsen, J.L., Wisloff, F., Brinch, L., Carlson, K., Carlsson, M., Dahl, I.M., Gimsing, P., Hippe, E., Johnsen, H., Lamvik, J., Lofvenberg, E., Nesthus, I. & Rodjer, S. (2000) Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood, 95, 7-11.
22. Lokhorst, H.M., Sonneveld, P. & Verdonck, L.F. (1999) Intensive treatment for multiple myeloma: where do we stand? British Journal of Haematology, 106, 18-27.
23. Mehta, J., Tricot, G., Jagannath, S., Ayers, D., Singhal, S., Siegel, D., Desikan, K., Munshi, N., Fassas, A., Mattox, S., Vesole, D., Crowley, J. & Barlogie, B. (1998) Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplantation. 21, 887-892.
24. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood, 99, 731-735.
25. Myeloma Trialists' Collaborative Group. (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Journal of Clinical Oncology, 16, 3832-3842.
26. Segeren, C.M., Sornneveld, P., van der Holt, B., Vellenga, E., Croockewit, A.J., Verhoef, G.E.G., Cornelissen, J.J., Schaafsma, M.R., van Oers, M.H.J., Wijermans, P.W., Fibbe, W.E., Wittebol, S., Schouten, H.C., van Marwijk Kooy, M., Biesma, D.H., Baars, J.W., Westveer, P., Steijaert, M.M.C. & Lokhorst, H.M. (2001) Intensive versus double Intensive therapy In previously untreated multiple myeloma: a prospective randomized phase III study in 450 patients. Presented at VIIIth International Myeloma Workshop. Banff, Alberta, May 4-8.
27. Ventura, G.J., Barlogie, B., Hester, J.P., Yau, J.C., LeMaistre, C.F., Wallerstein, R.O., Spinolo, J.A., Dicke, K.A., Horwitz, L.H. & Alexanian, R. (1990) High dose cyclophosphamide. BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. Bone Marrow Transplantation, 5, 265-268.